Article
Clinical Neurology
Michael Dietrich, Hans-Peter Hartung, Philipp Albrecht
Summary: 4-aminopyridine is used as a symptomatic therapy in various neurological disorders, with potential neuroprotective features beyond its symptomatic action, particularly in patients with multiple sclerosis.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2021)
Article
Biochemical Research Methods
Sheba M. K. Chalil, Indukala P. Chandrasekharan, Singaram Kathirvel, Raja R. Katta
Summary: Fampridine is a drug used to improve walking in multiple sclerosis patients. A dried blood spot (DBS) sampling method is developed as an alternative to plasma monitoring, allowing for simplified sample storage and transport. The correlation between DBS and plasma concentrations is determined, validating DBS sampling as a simple and practical method for monitoring fampridine concentrations.
JOURNAL OF CHROMATOGRAPHIC SCIENCE
(2023)
Article
Clinical Neurology
Cecilie Dollerup Skov, Christina Borgen Sorensen, Maria Thorning, Kate Lykke Lambertsen, Lars Henrik Frich, Henrik Boye Jensen, Anders Holsgaard-Larsen, Helle H. Nielsen
Summary: The purpose of this study was to evaluate changes in functional hand and walking measurements in multiple sclerosis patients with walking disability after fampridine treatment. The combination of self-reported walking capacity and walking endurance was found to be the most effective measurement for detecting clinically meaningful improvement after fampridine treatment.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Clinical Neurology
Maria A. Rocca, Paola Valsasina, Bruno Colombo, Vittorio Martinelli, Massimo Filippi
Summary: Fatigue in multiple sclerosis patients improved regardless of treatment. Changes in resting state functional connectivity were located in sensorimotor, inferior frontal, and subcortical regions for fampridine- and amantadine-treated patients, while in associative sensory cortices for placebo-treated patients.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Review
Clinical Neurology
Sahar Ghorbanpour, Sarvenaz Rahimibarghani, Setareh Rohani, Mohsen Rastkar, Mahsa Ghajarzadeh
Summary: This systematic review and meta-analysis found that fampridine improves gait imbalance in patients with multiple sclerosis (MS).
NEUROLOGICAL SCIENCES
(2023)
Article
Clinical Neurology
Sepehr Mamoei, Henrik Boye Jensen, Andreas Kristian Pedersen, Mikkel Karl Emil Nygaard, Simon Fristed Eskildsen, Ulrik Dalgas, Egon Stenager
Summary: In a 1-year longitudinal study, responders and non-responders to Fampridine treatment among persons with multiple sclerosis were compared in terms of disability measures, physical and cognitive performance tests, neurophysiology, and MRI outcomes. Non-responders were found to have prolonged peripheral motor conduction times compared to responders. The study also showed associations between certain tests and measurements, such as the six spot step test with central motor conduction times and the symbol digit modalities test with T2-weighted lesion characteristics.
FRONTIERS IN NEUROLOGY
(2021)
Article
Immunology
Nesrine Ahras-Sifi, Fatima Laraba-Djebari
Summary: IL-4 treatment has been shown to reduce neuronal death induced by potassium-channel dysfunction in a murine model of neuroexcitotoxicity, likely through mechanisms such as decreasing mitochondria swelling, reversing oxidative damage, and enhancing Bcl-2 expression. Additionally, IL-4 treatment also reduced TNF-α expression and increased GFAP and IL-10 expressions in the brain, indicating its neuroprotective effect in epileptogenesis.
JOURNAL OF NEUROIMMUNOLOGY
(2021)
Editorial Material
Clinical Neurology
Priyanka Iyer, Ruth Dobson
Summary: Multiple sclerosis (MS) is more common in women and many women are diagnosed before completing their families. This leads to complicated decisions regarding the use of disease-modifying therapies during pregnancy, for which there is limited evidence. Conversations between clinicians and women with MS regarding pregnancy often do not address all the issues due to limited available information. Consensus guidelines have been developed recently, using both experience and expert opinion. This paper provides a practical overview of the safety of treatments for MS and its symptoms during pregnancy and breastfeeding.
NEUROLOGY AND THERAPY
(2023)
Article
Pharmacology & Pharmacy
Alexey I. Kuzmenkov, Andrei M. Gigolaev, Ernesto L. Pinheiro-Junior, Steve Peigneur, Jan Tytgat, Alexander A. Vassilevski
Summary: Previous studies have identified key amino acid residues in scorpion toxins that block potassium channels, particularly in the α-KTx family affecting voltage-gated potassium channels (KV). A conserved K-C-X-N motif is found in the C-terminal half of their sequence, with the X position usually occupied by methionine or isoleucine. Comparing the activity of peptides differing only by this residue on a panel of KV1 channels, it was found that toxins with methionine specifically affect KV1.1 and 1.6 isoforms. The refined K-C-M/I-N motif is the principal structural element of α-KTx that contributes to high affinity and selectivity to KV channels.
Article
Cell Biology
Ulrike B. S. Hedrich, Stephan Lauxmann, Markus Wolff, Matthis Synofzik, Thomas Bast, Adrian Binelli, Jose M. Serratosa, Pedro Martinez-Ulloa, Nicholas M. Allen, Mary D. King, Kathleen M. Gorman, Bruria Ben Zeev, Michal Tzadok, Lily Wong-Kisiel, Dragan Marjanovic, Guido Rubboli, Sanjay M. Sisodiya, Florian Lutz, Harshad Pannikkaveettil Ashraf, Kirsten Torge, Pu Yan, Christian Bosselmann, Niklas Schwarz, Monika Fudali, Holger Lerche
Summary: Developmental and epileptic encephalopathies are severe disorders characterized by epilepsy, intellectual disability, and other neuropsychiatric symptoms with limited treatment options. Through a precision medicine approach, it was found that the K+ channel blocker 4-aminopyridine could effectively alleviate symptoms in patients with KCNA2-encephalopathy caused by variants in the K(V)1.2 subunit. Results from n-of-1 trials showed that most patients benefited from the treatment with 4-aminopyridine, with well-tolerated dosages up to 2.6 mg/kg per day.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Fumiya Tamura, Shintaro Sugimoto, Mana Sugimoto, Kazuho Sakamoto, Masahiko Yamaguchi, Takeshi Suzuki, Keiichi Fukuda, Masaki Ieda, Junko Kurokawa
Summary: The synthetic estrogen ethinylestradiol (EE2) did not significantly affect hERG currents at supratherapeutic concentrations but reduced the degree of hERG current suppression by E-4031 at therapeutic concentrations. The findings suggest a potential interaction between EE2 and E-4031 altering hERG function at the drug-binding site.
Article
Agricultural Engineering
Qian Zhu, Jingping Hu, Bingchuan Liu, Sha Liang, Keke Xiao, Wenbo Yu, Shushan Yuan, Jiakuan Yang, Huijie Hou
Summary: This study investigated the effects of adding tetraethylammonium (TEA), a potassium channel blocker, on the formation of mixed-cultured electroactive biofilms. The results showed that TEA decelerated biofilm formation but selectively enriched Geobacter over time, resulting in higher extracellular electron transfer efficiency. The analysis also indicated adaptive responses of electrogenic biofilms to electrical signaling disruption.
BIORESOURCE TECHNOLOGY
(2022)
Article
Genetics & Heredity
Rahul Rajendran, Rahul Krishnan, Jong -Oh Kim, Myung-Joo Oh
Summary: Ion channels in fishes play an important role in the excitation and transmission of impulses through neuronal cells. This study reveals that the expression of potassium channel genes changes during NNV infection in the sevenband grouper, and the downregulation of these genes is associated with viral replication. These findings suggest that potassium channels play a crucial role during viral infection.
Article
Clinical Neurology
Sophie F. Hill, Julie M. Ziobro, Paymaan Jafar-Nejad, Frank Rigo, Miriam H. Meisler
Summary: Voltage-gated sodium and potassium channels play a crucial role in regulating neuronal action potentials, and mutations in these channels can lead to seizure disorders. This study demonstrates that reducing the expression of Scn8a can compensate for loss-of-function mutations in Kcna1 and Kcnq2, providing a potential therapeutic approach for genetic epilepsies caused by mutations in potassium channel genes.
Article
Clinical Neurology
Ali Amini Harandi, Hossein Pakdaman, Faezeh Karamiani, Faezeh Mohammadi, Siavash Shirzadeh Barough, Fatemeh Siavoshi, Saba Ilkhani, Mohammadali Sahraian
Summary: Using fampridine plus IVMP in the acute phase of transverse myelitis in MS patients improved the disease's symptoms and increased the daily activity ability of patients.
NEUROLOGICAL SCIENCES
(2023)
